NVCR - NovoCure Limited

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
42.70
-2.34 (-5.20%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close45.04
Open45.11
Bid42.50 x 900
Ask42.80 x 1200
Day's Range42.53 - 45.85
52 Week Range16.90 - 53.70
Volume621,736
Avg. Volume760,001
Market Cap3.95B
Beta (3Y Monthly)3.29
PE Ratio (TTM)N/A
EPS (TTM)-0.65
Earnings DateOct 25, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est58.50
Trade prices are not sourced from all markets
  • Gauging Analysts’ Views for NovoCure Stock
    Market Realist2 days ago

    Gauging Analysts’ Views for NovoCure Stock

    Of the five analysts covering NovoCure (NVCR) stock in October, two have given it a “strong buy,” and three have given it a “buy.” The mean rating for NovoCure is 1.6 with a target price of $56.50. That implies an upside potential of 24.4% over its trading price of $45.42 on October 18.

  • NovoCure’s Operational Performance in Q3 2018: What to Expect
    Market Realist2 days ago

    NovoCure’s Operational Performance in Q3 2018: What to Expect

    NovoCure’s (NVCR) gross income is expected to rise 28.22% to $44.82 million in the third quarter of 2018. Its gross margin is expected to contract from 69.76% in the third quarter of fiscal 2017 to 68.7% in the third quarter of fiscal 2018. NovoCure’s gross margins for fiscal 2018 and fiscal 2019 are expected to be 67.97% and 72.72%, respectively.

  • NovoCure: Its Top-Line Forecast for Q3 2018
    Market Realist2 days ago

    NovoCure: Its Top-Line Forecast for Q3 2018

    NovoCure (NVCR) is expected to report its third quarter of fiscal 2018 earnings on October 25. NovoCure’s clinical programs are evaluating the use of tumor-treating fields in various indications, including brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, and liver cancer. Analysts expect NovoCure’s revenues to increase 30.47%, from $50.11 million in the third quarter of fiscal 2017 to $65.38 million in the third quarter of fiscal 2018.

  • NovoCure (NVCR) Q3 Earnings Preview: What to Look Out For
    Zacks3 days ago

    NovoCure (NVCR) Q3 Earnings Preview: What to Look Out For

    NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire3 days ago

    Novocure Announces that the Medicare DME MACs Have Accepted the Local Coverage Determination Reconsideration Request for Optune®

    Novocure (NVCR) announced today that the durable medical equipment (DME) Medicare administrative contractors (MACs) have accepted our local coverage determination (LCD) reconsideration request for the treatment of newly diagnosed glioblastoma (GBM) and plan to take steps to publish a final LCD for newly diagnosed GBM. Per Centers for Medicare & Medicaid Services (CMS) and Medicare policy, the two DME MACs will issue a single joint policy applicable in all DME regions.

  • Why Novocure Stock Jumped 16.3% in September
    Motley Fool10 days ago

    Why Novocure Stock Jumped 16.3% in September

    Shares of this medical device company that's aiming to revolutionize cancer treatment are up 123% in 2018.

  • Business Wire17 days ago

    Novocure Announces 55 Presentations at European Association of Neuro-Oncology Meeting 2018

    Highlights include a data analysis of EF-14 that demonstrated an increased dose of Tumor Treating Fields to the tumor bed improved overall survival in GBM patients as well as safet

  • 3 Medical Devices Stocks to Buy
    InvestorPlace19 days ago

    3 Medical Devices Stocks to Buy

    When you think of medical devices stocks, you don’t think of cloud-connected watches. You want to invest in more prosaic companies, large and small, which offer discrete devices for specific conditions, with Food and Drug Administration (FDA) approvals and positive clinical trials. The long-term prognosis for medical devices is good, but many companies need to deal with short-term problems to get there, so look for strength – financial strength or strength within a winning niche – when you shop for investments.

  • Business Wire20 days ago

    Novocure to Report Third Quarter 2018 Financial Results

    Novocure announced today that it will report financial results for the third quarter 2018 on Thursday, October 25, 2018, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three and nine months ended September 30, 2018, at 8 a.m.

  • Business Wire26 days ago

    Data from STELLAR Registration Trial of Tumor Treating Fields in Mesothelioma to be Presented at the IASLC 19th World Conference on Lung Cancer

    Mesothelioma patients who received Tumor Treating Fields with pemetrexed and cisplatin or carboplatin experienced median overall survival of 18.2 months compared to 12.1 months in

  • What Investors Should Know About NovoCure Limited’s (NASDAQ:NVCR) Financial Strength
    Simply Wall St.last month

    What Investors Should Know About NovoCure Limited’s (NASDAQ:NVCR) Financial Strength

    Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as NovoCure Limited (NASDAQ:NVCR) with a market-capitalization of US$4.36b, rarely draw their attention. However, history shows that overlookedRead More...

  • 5 Medical Device Stocks With Impressive Staying Power
    InvestorPlacelast month

    5 Medical Device Stocks With Impressive Staying Power

    Easily the biggest trend in investing has to be healthcare stocks. From rising and aging populations in the developed world to new middle-class consumers gaining access to healthcare for the first time in emerging markets, healthcare demand is only getting bigger by the day. All in all, the combination of the two factors makes the medical device stocks some of best plays in all of healthcare.

  • Business Wirelast month

    Novocure and Zai Lab Announce Strategic Collaboration with a License Agreement for Tumor Treating Fields in Greater China

    Novocure (NVCR), a global oncology company developing a proprietary platform technology called Tumor Treating Fields, and Zai Lab (ZLAB), a Shanghai-based innovative biopharmaceutical company, announced today an exclusive license agreement for Tumor Treating Fields, including the brand name Optune, in Greater China and a global strategic development collaboration. This agreement will enable Novocure to access the Chinese market and is intended to accelerate clinical trial enrollment.

  • Why Novocure Gained 33% in August
    Motley Foollast month

    Why Novocure Gained 33% in August

    Wall Street is excited about the growing potential for the company's cancer-fighting treatments.

  • NovoCure Stock Rose after Positive Results from Clinical Trial
    Market Realistlast month

    NovoCure Stock Rose after Positive Results from Clinical Trial

    On September 6, NovoCure (NVCR) stock rose 5.3% to reach $45.40 compared to the previous day’s close of $43.10. Also, on September 6, NovoCure hit its 52-week high of $46.73. Its closing price for the day represents ~182% growth from its 52-week low of $16.10 on October 13, 2017.

  • Stocks - Cloudera, Verint Systems, Novocure Soar in Pre-market; Lands' End Tumbles
    Investing.comlast month

    Stocks - Cloudera, Verint Systems, Novocure Soar in Pre-market; Lands' End Tumbles

    Investing.com - Stocks in focus in pre-market trade Thursday:

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Spectrum Pharmaceuticals and NovoCure

    NEW YORK, NY / ACCESSWIRE / September 6, 2018 / Major U.S. equities were mixed on Wednesday with tech stocks posting worst daily drop since July dragging Nasdaq lower. The Dow Jones Industrial Average ...

  • Business Wire2 months ago

    Tumor Treating Fields Plus Standard of Care Chemotherapy Significantly Extends Median Overall Survival by 6.1 Months in STELLAR Phase 2 Registration Trial in Mesothelioma Compared to Historical Control

    Novocure (NVCR) announced final results from its STELLAR phase 2 registration trial in mesothelioma, demonstrating a significant extension in median overall survival among patients treated with Tumor Treating Fields plus standard of care chemotherapy compared to historical control data of patients who received standard of care chemotherapy alone. Malignant pleural mesothelioma patients who received Tumor Treating Fields with pemetrexed and cisplatin or carboplatin experienced median overall survival of 18.2 months (95 percent CI, 12.1-25.8 months) compared to 12.1 months in a historical control.

  • This brain cancer drug stock has been on a tear
    Yahoo Finance2 months ago

    This brain cancer drug stock has been on a tear

    This year, more than 14,000 people in the U.S. will be diagnosed with the same kind of brain cancer that killed Senator John McCain, glioblastoma multiforme, or GBM. 

  • Motley Fool2 months ago

    3 Small-Cap Healthcare Stocks for Your Watch List

    These hidden gems found a niche for themselves and rocked it, and they’re just getting started.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Exact Sciences and NovoCure

    NEW YORK, NY / ACCESSWIRE / August 24, 2018 / U.S. markets plunged on Thursday following the release of the minutes from the latest Federal Reserve meeting, which called for an interest hike in September. ...

  • GlobeNewswire2 months ago

    Research Report Identifies Genesis Healthcare, Maiden, Ichor, Armstrong World Industries, Rexnord, and NovoCure with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Aug. 23, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Genesis ...

  • What Does NovoCure’s Valuation Trend Indicate?
    Market Realist2 months ago

    What Does NovoCure’s Valuation Trend Indicate?

    NovoCure’s (NVCR) net financial expenses increased from $2.18 million in the second quarter of 2017 to $2.86 million in the second quarter. NovoCure’s income tax expenses also increased from $3.46 million in the second quarter of 2017 to $5.56 million in the second quarter.

  • NovoCure Stock: Key Factors Driving Investors’ Interest
    Market Realist2 months ago

    NovoCure Stock: Key Factors Driving Investors’ Interest

    NovoCure (NVCR) is mainly engaged in developing and bringing tumor treating fields for solid tumors to the market. The company’s first tumor treating fields delivery system, Optune, is targeted to treat adult patients with glioblastoma. Tumor treating fields use electric fields tuned to certain frequencies to disrupt solid tumor cancer cell division.

  • NovoCure’s Top Line Registered Strong Growth
    Market Realist2 months ago

    NovoCure’s Top Line Registered Strong Growth

    NovoCure (NVCR) generated revenues of $61.51 million in the second quarter—compared to $38.38 million in the second quarter of 2017. The growth was also driven by NovoCure’s initial launch efforts in Japan. NovoCure incurred a cost of revenues of $19.83 million in the second quarter—compared to $13.15 million in the second quarter of 2017.